# Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

> **NCT03567889** · PHASE3 · RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 186 (estimated)

## Conditions studied

- Melanoma Stage IIIB
- Melanoma Stage IIIC
- Melanoma Stage IIID

## Interventions

- **DRUG:** Daromun
- **PROCEDURE:** Surgery
- **DRUG:** Adjuvant therapy

## Key facts

- **NCT ID:** NCT03567889
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-20
- **Primary completion:** 2027-12
- **Final completion:** 2031-12
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567889, "Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03567889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*